China Resources Pharmaceutical Group Ltd (SEHK: 03320) has announced that its wholly-owned subsidiary, China Resources Pharmaceutical Holdings Limited, has completed the issuance of the third tranche of 2026 medium-term notes in China.
The third tranche of 2026 medium-term notes, with a principal amount of RMB 800 million, has been issued with a term of three years and a coupon rate of 1.45% per annum.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.